Gecacitinib for chronic graft-versus-host disease that is steroid-resistant or dependent
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new oral medication called Gecacitinib for people who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose cGVHD is not fully controlled or requires long-term steroids. It aims to see if Gecacitinib can help manage symptoms and reduce steroid use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a stem cell transplant for a blood cancer or other blood disorder.
- You have active chronic GVHD that has not improved with steroids or you need a daily steroid dose of more than 5–10 mg of prednisone to keep it under control.
- Your blood counts (platelets and neutrophils) are within a certain range without needing growth factors or transfusions in the last week.
- Your liver and kidney function are adequate (based on blood tests).
- You are feeling well enough to be up and about (Karnofsky performance status 60% or higher).
- You have not used other JAK inhibitor medications before or currently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking Gecacitinib before, during, and after a stem cell transplant helps patients with myelofibrosis. The goal is to see if the drug can improve transplant outcomes and reduce complications.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This trial tests an experimental drug called Iguratimod for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see if the drug can safely control cGVHD symptoms when other treatments haven't worked well enough.
This study tests two medications (belumosudil and ruxolitinib) together for chronic graft-versus-host disease (cGvHD)—a condition where transplanted immune cells attack your body—that did not improve with steroid treatment alone. The trial aims to help patients whose disease is resistant to standard steroids.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.